Back to Journals » Drug Design, Development and Therapy » Volume 4

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

Authors Warnke C, Wiendl H, Hartung H, Stüve O, Kieseier B

Published 18 June 2010 Volume 2010:4 Pages 117—126


Review by Single anonymous peer review

Peer reviewer comments 3

Clemens Warnke1, Heinz Wiendl2, Hans-Peter Hartung1, Olaf Stüve3, Bernd C Kieseier1

1Department of Neurology, Heinrich-Heine University Düsseldorf, Germany; 2Department of Neurology – Inflammatory Disorders of the Nervous System and Neurooncology, University of Münster, Germany; 3Department of Neurology, Dallas VA Medical Center and UT Southwestern Medical Center, Dallas, Texas, USA

Abstract: Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.

Keywords: immunosuppressant, oral drugs, risk–benefit, safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.